Clinical Biomarker-Based Biological Aging and the Risk of 1

Abdominal Aortic Aneurysm: A Prospective Cohort Study 2

- Xinyi Zhou^{1,2#}, Zaixin Yu^{1,2#}, Mukamengjiang Juaiti^{1,2}, Lihuang Zha^{1,2}, Baohua 3
- Peng^{1,2}, Chengshuang Xiao^{1,2}, Yivang Tang^{1,2*} 4
- ¹Department of Cardiology, Xiangya Hospital, Central South University, Changsha, 5
- Hunan, China. 6
- ²National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central 7
- South University, Changsha, Hunan, China. 8
- [#]These authors contributed equally to this work. 9
- * Correspondence: 10
- Yiyang Tang, MD 11
- 12 Email: tangyiyang@csu.edu.cn
- Address: No.87 Xiangya Road, Kaifu District, Changsha, Hunan, China. 13

14 Abstract

15	Background: Compared to chronological age, biological age (BA), a concept
16	introduced in recent years, more accurately reflects the true aging status of the body.
17	While biological aging has been found to be associated with various cardiovascular
18	diseases, its relationship with abdominal aortic aneurysm (AAA) remains unclear.
19	Methods: This study utilized data extracted from UK Biobank for analysis. Telomere
20	length (TL), and BA acceleration calculated using the Klemera-Doubal (KDM) and
21	PhenoAge methods, were employed as surrogate measures to assess biological aging.
22	Cox regression was primarily performed to explore the association between biological
23	aging and AAA risk. Genetic susceptibility was assessed by constructing a polygenic
24	risk score (PRS).
25	Results: This study included 311,646 participants, predominantly women and White,
26	with a median age of 58 years. During a median follow-up of 12.54 years, 1,339 new
27	cases of AAA (4.3‰) were reported. Each standard deviation (SD) decrease in TL
28	was associated with a 20% increased risk of AAA (HR=1.20, 95% CI=1.14-1.27);
29	each SD increase in KDM-BA acceleration was associated with a 21% increased risk
30	(HR=1.21, 95% CI=1.12-1.29); and each SD increase in PhenoAge acceleration was
31	associated with a 40% increased risk (HR=1.40, 95% CI=1.32-1.48). These
32	associations were independent of genetic risk, as assessed by the PRS, and
33	demonstrated a joint effect with genetic predisposition on the long-term risk of AAA.

- 34 Conclusion: Accelerated biological aging was longitudinally associated with an
- 35 increased risk of AAA, suggesting it may be a significant factor and potential
- 36 biomarker for the occurrence of the condition.
- 37 Keywords: Biological aging, Abdominal aortic aneurysm, UK Biobank, Genetic
- 38 susceptibility.

39 Background

40 Abdominal aortic aneurysm (AAA) is the most common form of aortic aneurysm, 41 characterized by the permanent and localized dilation of the abdominal aorta[1]. It is 42 often asymptomatic until rupture, a catastrophic event with a mortality rate of up to 43 80%, highlighting its significant public health burden[2]. Therefore, identifying and 44 validating biomarkers associated with AAA occurrence is of significant public health 45 importance, as it can enhance early diagnosis, improve management strategies, and 46 ultimately optimize patient outcomes.

47 AAA is a degenerative disease associated with aging[3]. Traditionally, chronological age has been used to assess an individual's level of aging and disease risk[4]. 48 49 However, chronological age has limitations, as individuals of the same or similar 50 chronological age can exhibit significant differences in functional status and aging processes due to factors such as genetics, environment, and lifestyle^[5]. Recently, 51 biological age has been proposed as a more comprehensive and accurate measure of 52 53 aging, incorporating indicators such as telomere length (TL), Klemera-Doubal method biological age (KDM-BA), and phenotypic age (PhenoAge)[6]. Previous studies have 54 shown that increased biological age is significantly associated with higher mortality 55 and elevated risks of various cardiovascular diseases, including heart failure[7, 8]. 56 However, the relationship between biological aging and the incidence of AAA 57 remains unclear. Additionally, AAA has a genetic predisposition, with genome-wide 58 association studies (GWAS) identifying several single-nucleotide polymorphisms 59

60	(SNPs) linked to AAA risk[9, 10]. The interaction between genetic susceptibility and
61	biological aging in relation to AAA risk has not yet been fully explored.

To fill this research gap, this study uses a prospective cohort from the UK Biobank to examine the longitudinal associations between biological aging and AAA risk, and to investigate the joint effects and interactions between genetic susceptibility and biological aging on the long-term risk of AAA.

66 Methods

67 Study population

The data used in this study were obtained from the UK Biobank (ID: 107175). The UK Biobank is a large-scale prospective cohort study that recruited over 500,000 volunteers across the United Kingdom between 2006 and 2010[11]. This study received ethical approval from the North West Multi-Centre Research Ethics Committee (Ref: 11/NW/0382), and all participants provided informed consent by signing a consent form.

Of the 502,163 participants in the UK Biobank, we excluded 460 participants with baseline AAA, 177,504 participants missing biomarkers required for the KDM-BA and PhenoAge algorithms, 11,531 participants missing TL measurements, and 1,022 participants with missing covariate data. A total of 311,646 participants were included in the final analysis. The participant selection process was shown in **Figure S1**.

79 Study Outcomes

80 The outcome variable of this study was the occurrence of AAA, which was 81 determined based on hospital admission and death registration records (**Table S1**).

82	The diagnosis of AAA was identified using the Tenth Revision of the International
83	Classification of Diseases (ICD-10 codes: I71.3, I71.4) and the Office of Population,
84	Censuses and Surveys: Classification of Interventions and Procedures (OPCS-4 codes:
85	L18*, L19*, L254, L27*, L28*, L464), as used in prior studies[12]. The study period
86	began when participants entered the cohort and ended upon the diagnosis of AAA,
87	loss to follow-up, death, or completion of follow-up, whichever occurred first. The
88	follow-up cut-off date was September 30, 2021, for England and Wales, and October
89	31, 2021, for Scotland.

90 Measurement of TL

91 TL was measured using a multiplex quantitative polymerase chain reaction method, 92 with samples obtained from peripheral blood leukocytes. Specifically, TL was 93 quantified relative to the ratio of telomere repeat copy number to single-copy gene 94 (T/S), and the data were log-transformed and Z-standardized. Detailed information on 95 the measurement and adjustment of TL can be found in previous studies[13].

96 Calculation of KDM-BA and PhenoAge

The KDM-BA and PhenoAge algorithms[8, 14, 15] are widely recognized biological 97 98 age measures based on clinical parameters (Table S2). These algorithms were developed using optimal training models derived from the National Health and 99 Nutrition Examination Survey (NHANES) and have been further validated with data 100 from UK 101 the Biobank. Using the R package "BioAge" 102 (https://github.com/dayoonkwon/BioAge), KDM-BA was calculated based on forced expiratory volume in one second, systolic blood pressure, and seven blood chemistry 103

parameters: albumin, alkaline phosphatase, blood urea nitrogen, creatinine, C-reactive 104 protein (CRP), glycated hemoglobin, and total cholesterol. PhenoAge was calculated 105 106 using nine hematological indicators: albumin, alkaline phosphatase, creatinine, CRP, glucose, mean corpuscular volume, red cell distribution width, white blood cell count, 107 108 and lymphocyte percentage. We then regressed the calculated biological age values against the chronological age at the time of biomarker measurement and computed the 109 residuals[16]. These residuals were termed "age acceleration" (AA) values, which 110 111 were used to assess biological aging. The AA values were then standardized with a 112 mean of 0 and a standard deviation of 1 for comparison in subsequent analyses. More details can be found in Method S1. 113

114 Covariates

The covariates considered in this study mainly included age, sex, ethnicity, education level, Townsend Deprivation Index (TDI), CRP, body mass index (BMI), smoking and alcohol consumption status, physical activity, sleep and dietary patterns, as well as medical history of hyperlipidemia, hypertension, and diabetes. Detailed definitions and descriptions of these covariates can be found in **Method S2**.

120 Statistical analysis

The continuous variables were found not to follow a normal distribution based on the quantile-quantile plot and were therefore expressed as medians [interquartile range (IQR)]. Group comparisons were performed using the Mann-Whitney U test or Kruskal-Wallis H test. Categorical variables were represented as frequencies (percentages), and group comparisons were conducted using chi-square tests.

TL, KDM-BA, and PhenoAge acceleration were treated as continuous variables or 126 categorized based on quartiles, and their associations with AAA occurrence were 127 128 assessed using Cox proportional hazards models, with results presented as hazard ratios (HR) and 95% confidence intervals (95% CI). The Schoenfeld residual test 129 130 confirmed no violations of the proportional hazards assumption. Model 1 adjusted for 131 age, sex, ethnicity, education level, and TDI. Model 2 further adjusted for smoking and drinking status, physical activity, sleep and dietary patterns, BMI, CRP, and 132 medical history of hypertension, hyperlipidemia, and diabetes. Additionally, based on 133 134 Cox regression Model 2, a restricted cubic spline (RCS) with three knots was used to analyze the dose-response relationship between biological aging and AAA risk. 135 136 We included only participants of White ancestry and constructed a polygenic risk 137 score (PRS) to assess individuals' genetic susceptibility to AAA[17] (Method S3). We then evaluated the joint effect of genetic susceptibility and biological aging on the 138 risk of AAA. Participants were categorized into 12 groups based on their levels of 139 140 biological aging and genetic susceptibility. Using the group with the lowest levels of both biological aging and genetic susceptibility as a reference, we estimated the HR 141 142 and 95% CI for AAA occurrence in the other groups, after adjusting for covariates in Model 2. Stratified analyses were conducted to assess the separate effect of biological 143 aging on AAA incidence at different levels of genetic susceptibility, and the 144 likelihood ratio test was used to evaluate the interaction between biological aging and 145 146 genetic susceptibility.

Subgroup analyses were also conducted to assess potential modifying effects on the association between biological aging and the risk of AAA. Sensitivity analyses included: 1. Excluding participants who developed AAA within the first year of follow-up; 2. Using the Fine-Gray model to account for mortality as a competing risk. All analyses were performed in R (version 4.3.2), with *p*-values < 0.05 considered statistically significant.

153 **Results**

154 **Baseline of the participants**

155 This study included a total of 311,646 participants (Figure S1), of whom 168,249 (54.0%) were women. The majority of participants were White, comprising 294,574 156 individuals or 94.5% of the total cohort (Table S3). The median age was 58 years 157 158 (IQR: 50-63 years), with median values of KDM-BA and PhenoAge recorded at 49.82 years (IQR: 40.90-58.26) and 45.83 years (IQR: 38.10-52.54), respectively. 159 160 KDM-BA (r = 0.67) and PhenoAge (r = 0.86) were strongly positively correlated with 161 chronological age, whereas TL showed a weak negative correlation (r = -0.20, Figure 162 **S2**).

Baseline characteristics, stratified by quartiles of TL, PhenoAge acceleration, and KDM-BA acceleration, were summarized in **Table 1** and **Tables S4–S5**. Participants with shorter TL were more likely to be men, have lower educational attainment, and engage in unhealthy lifestyle behaviors (e.g., current smoking, poor sleep patterns, and insufficient physical activity). They also exhibited higher prevalence rates of diabetes, hyperlipidemia, and hypertension. Similar trends were observed for baseline

169 characteristics stratified by quartiles of KDM-BA acceleration and PhenoAge170 acceleration.

171 Association between biological aging and the risk of AAA

During a median follow-up of 12.54 years (IOR: 11.87-13.16), a total of 1,339 (4.3‰) 172 173 incident cases of AAA were reported. Overall, accelerated biological aging was significantly positively associated with an increased long-term risk of AAA (Table 2). 174 Specifically, for each standard deviation decrease in TL, the risk of AAA increased by 175 20% (HR = 1.20, 95% CI = 1.14-1.27); for each standard deviation increase in 176 177 KDM-BA acceleration, the risk increased by 21% (HR = 1.21, 95% CI = 1.12-1.29); and for each standard deviation increase in PhenoAge acceleration, the risk increased 178 179 by 40% (HR = 1.40, 95% CI = 1.32-1.48). Consistently, compared with participants 180 with longer TL, lower KDM-BA acceleration, or lower PhenoAge acceleration, those with shorter TL, higher KDM-BA acceleration, or higher PhenoAge acceleration had 181 significantly higher risks of AAA. Furthermore, Figure 1 demonstrated the potential 182 183 dose-response relationships between biological aging and AAA risk. The results indicated a linear association between TL, KDM-BA acceleration, PhenoAge 184 acceleration, and AAA occurrence (*p*-value for non-linearity > 0.05). 185

186 Joint and interaction analysis of biological aging and genetic predisposition

The results in **Table S6** indicated that the constructed PRS score effectively predicted the risk of AAA occurrence. After further adjusting for PRS in Models 1 and 2, the significant association between biological aging indicators and AAA risk persisted (**Table S7**).

191	The joint effects of biological aging and genetic susceptibility on the risk of AAA
192	were shown in Figure 2A-C. Overall, the risk of AAA increased with accelerated
193	biological aging and higher levels of genetic susceptibility (<i>p</i> -value for trend < 0.001).
194	Compared to participants with the lowest PRS and biological aging, those with the
195	highest PRS and biological aging exhibited the highest risk of AAA (high PRS and Q1
196	of TL: HR = 1.81, 95% CI = 1.31-2.49; high PRS and Q4 of KDM-BA acceleration:
197	HR = 2.43, 95% CI = 1.79-3.28; high PRS and Q4 of PhenoAge acceleration: $HR =$
198	3.27, 95% CI = 2.21-4.85). Additionally, at different levels of genetic susceptibility,
199	higher levels of biological aging were positively associated with the occurrence of
200	AAA (Figure 2D-F). No significant interaction was observed between genetic
201	susceptibility and biological aging indicators regarding the risk of AAA (p-value for
202	interaction > 0.05).

203

Subgroup and sensitivity analyses

As shown in Table 3, subgroup analyses indicated that the association between 204 shortened TL and the incidence of AAA was significant only in men, rather than in 205 women (*p*-value for the interaction between sex and TL = 0.018). For other 206 stratification factors, no significant differences were observed in the associations 207 between biological aging indicators and AAA occurrence (*p*-value for the interaction > 208 0.05, Table S8-9). Sensitivity analyses, including the exclusion of participants who 209 reported AAA in the first year (Table S10) and the application of Fine-Gray 210 competing risk regression models (Figure S3), consistently supported the strong 211 association between high levels of biological aging and an increased incidence of 212

213 AAA.

214 Discussion

215 In this study, we utilized the large-scale prospective cohort of the UK Biobank to investigate the association between clinical biomarker-based biological aging and the 216 217 long-term risk of AAA. The main findings are as follows: accelerated biological aging (reflected by shortened TL, higher KDM-BA, and PhenoAge acceleration) was 218 significantly associated with an increased risk of AAA. This association was 219 independent of genetic risk assessed by PRS and demonstrated a joint effect with 220 221 genetic predisposition. Furthermore, sex appeared to modify the relationship between TL and AAA risk, with the association between shortened TL and an increased risk of 222 223 AAA being significant only in men.

224 The association between biological aging and cardiovascular diseases has gradually been recognized[18, 19], and accurately measuring biological age is key to further 225 studying this relationship[20]. To this end, various indicators for assessing an 226 227 individual's biological age have been proposed, each of which is distinctive in reflecting different dimensions and mechanisms of the aging process. Telomeres are 228 229 tandemly repeated nucleotide sequences located at the ends of chromosomes, and TL is considered a key indicator of biological aging[21]. When telomeres shorten to a 230 231 critical threshold, an irreparable DNA damage response is triggered, leading to the cessation of cell division and, consequently, aging[22]. A study by Atturu et al.[23] 232 showed that, compared to the control group, patients with AAA had shorter leukocyte 233 telomeres, and this telomere shortening was significantly associated with AAA (odds 234

ratio [OR] = 2.30, 95% CI = 1.28-4.13). However, this was a case-control study with a 235 limited sample size (N = 373), and it did not establish a longitudinal association 236 237 between TL and the occurrence of AAA. This study partially addressed this issue and provided stronger evidence. We also found an interesting interaction between TL and 238 239 sex. The association between biological aging and AAA risk was only significant in men. The remodeling of the extracellular matrix has been found to be more 240 pronounced in the aging process of men compared to women, as evidenced by 241 increased aortic diameter and stiffness[24]. This may be attributed to the protective 242 243 effects of estrogen[25]. In addition, several composite biomarker algorithms, such as KDM-BA and PhenoAge, have been proposed in recent years to estimate an 244 245 individual's biological age. Compared to single indicators like TL, these algorithms 246 are more reliable and comprehensive, as they integrate a range of clinical biomarkers and anthropometric data while also considering multiple dimensions, such as 247 metabolism, immunity, inflammation, and organ homeostasis[26]. Furthermore, their 248 high accessibility and affordability further enhance their potential for widespread 249 application. 250

Biological aging may contribute to the development of AAA through various mechanisms. Chronic low-grade inflammation is a significant characteristic of aging and a key mechanism in AAA development. Senescent cells secrete a complex array of factors, including pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases[27]. These factors can recruit various inflammatory cells to infiltrate the vascular wall, creating an inflammatory microenvironment that

compromises aortic structural integrity and promotes the occurrence of AAA[28]. 257 Additionally, oxidative stress may partly explain the association between biological 258 259 aging and AAA. Research has shown that aging is related to the dysfunction of nuclear factor E2-related factor 2 in the aorta, exacerbating oxidative stress and 260 increasing sensitivity to reactive oxygen species-mediated damage[29]. Moreover, the 261 phenotypic transformation of smooth muscle cells is another important mechanism in 262 the development of aortic aneurysms. Under pressure induction, aging vascular 263 smooth muscle cells secrete fibroblast growth factor 9, causing adjacent normal 264 265 vascular smooth muscle cells to undergo phenotypic transformation, which may contribute to the formation of AAA[30]. 266

The strength of this study lies in establishing, for the first time, a longitudinal 267 268 association between biological aging and the long-term risk of AAA. The large sample size and high-quality data from the UK Biobank prospective cohort ensured 269 the credibility of the study results. Additionally, this study is notably comprehensive, 270 271 utilizing three different indicators to assess individual biological aging levels: TL, a key marker of aging, and KDM-BA and PhenoAge, which are calculated based on 272 273 multidimensional biomarkers. Furthermore, we also took into account the role of genetic susceptibility in this association. This study also has some limitations. First, as 274 an observational study, it cannot establish causality or clarify the specific mechanisms 275 underlying the association between biological aging and AAA. Second, biological 276 aging was assessed solely through baseline data, preventing further exploration of the 277 relationship between longitudinal changes in biological aging and AAA risk. 278

279	Although multiple confounding factors were adjusted for, the study cannot rule out
280	the potential influence of important confounders not available in the UK Biobank.
281	Additionally, since the participants of the UK Biobank were primarily White, the
282	generalizability of the findings to other populations needs further confirmation.
283	Conclusion
283 284	Conclusion Biomarker-based biological aging is significantly associated with the long-term risk
283 284 285	Conclusion Biomarker-based biological aging is significantly associated with the long-term risk of AAA, independent of genetic susceptibility. These findings highlight the potential

287 providing valuable insights for its prevention and management.

288 Declarations

289 Ethics approval and consent to participate

- 290 This study was approved by the North West Multi-Centre Research Ethics Committee
- 291 (Reference: 11/NW/0382). All participants provided written informed consent prior to
- 292 participation.

293 **Consent for publication**

Not applicable.

295 Availability of data and materials

- 296 The data supporting the findings of this study were obtained from the UK Biobank
- 297 Resource under Application No. 107175. These data can be accessed by submitting an
- application through the UK Biobank official website (www.ukbiobank.ac.uk).

299 **Competing interests**

300 The authors declare no competing interests.

301 Funding

- 302 This work was supported by the National Natural Science Foundation of China (Grant
- Nos. 82470054 and 82300081), the Hunan Provincial Natural Science Foundation of
- 304 China (Grant Nos. 2023JJ40963, 2024JJ6620, and 2024JJ6673), and the Project
- 305 Program of the National Clinical Research Center for Geriatric Disorders (Xiangya
- 306 Hospital, Grant No. 2023LNJJ18).

307 Author contributions

308 This study was conceived and designed by Yiyang Tang. Xinyi Zhou and Zaixin Yu

309 performed the data analysis and drafted the manuscript. Mukamengjiang Juaiti and

310	Lihuang Zha contributed to the statistical analysis. Baohua Peng assisted with data							
311	interpretation and visualization. Chengshuang Xiao revised the manuscript and							
312	provided constructive feedback. All authors reviewed and approved the final							
313	manuscript.							
314	Ackno	owledgements						
315	The au	thors sincerely thank the management team and participants of the UK Biobank						
316	for the	ir invaluable contributions to this study.						
317	Refere	ence:						
318	[1]	Zhou M, Wang X, Shi Y, Ding Y, Li X, Xie T, et al. (2021). Deficiency of ITGAM						
319		Attenuates Experimental Abdominal Aortic Aneurysm in Mice. J Am Heart Assoc,						
320		10:e019900.						
321	[2]	Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, et al. (2019).						
322		Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical						
323		Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms.						
324		Eur J Vasc Endovasc Surg, 57:8-93.						
325	[3]	Wang D, Hao X, Jia L, Jing Y, Jiang B, Xin S (2022). Cellular senescence and						
326		abdominal aortic aneurysm: From pathogenesis to therapeutics. Front Cardiovasc						
327		Med, 9:999465.						
328	[4]	Fan H, Xie Q, Zhang Z, Wang J, Chen X, Qiu P (2021). Chronological Age Prediction:						
329		Developmental Evaluation of DNA Methylation-Based Machine Learning Models.						
330		Front Bioeng Biotechnol, 9:819991.						
331	[5]	Salih A, Nichols T, Szabo L, Petersen SE, Raisi-Estabragh Z (2023). Conceptual						

332 Overview of Biological Age Estimation. Aging Dis, 14:583-588.

- Zhang C, Ling Z, Xiang L, Zhang Y, Li L, Yang S, *et al.* (2024). Association of
 accelerated aging with the incidence risk of Cardiometabolic diseases in people with
 severe mental illnesses: A prospective analysis in UK Biobank. Psychiatry Res,
 336 337:115930.
- Mao R, Wang F, Zhong Y, Meng X, Zhang T, Li J (2024). Association of Biological Age
 Acceleration with Cardiac Morphology, Function, and Incident Heart Failure: Insights
 from UK Biobank Participants. Eur Heart J Cardiovasc Imaging.
- Liu Z, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M (2018). A new aging
 measure captures morbidity and mortality risk across diverse subpopulations from
 NHANES IV: A cohort study. PLoS Med, 15:e1002718.
- 343 [9] Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, et al. (2023).
- 344 Genome-wide association meta-analysis identifies risk loci for abdominal aortic
- aneurysm and highlights PCSK9 as a therapeutic target. Nat Genet, 55:1831-1842.
- 346 [10] Zheng S, Tsao PS, Pan C (2024). Abdominal aortic aneurysm and cardiometabolic
- traits share strong genetic susceptibility to lipid metabolism and inflammation. Nat
 Commun, 15:5652.
- 349 [11] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* (2015). UK biobank:
- an open access resource for identifying the causes of a wide range of complex
 diseases of middle and old age. PLoS Med, 12:e1001779.
- Ma Y, Li D, Cui F, Wang J, Tang L, Yang Y, *et al.* (2024). Air pollutants, genetic
 susceptibility, and abdominal aortic aneurysm risk: a prospective study. Eur Heart J,

- **45:1030-1039**.
- [13] Codd V, Denniff M, Swinfield C, Warner SC, Papakonstantinou M, Sheth S, *et al.*(2021). A major population resource of 474,074 participants in UK Biobank to
 investigate determinants and biomedical consequences of leukocyte telomere
 length.2021.2003.2018.21253457.
- Itevine ME (2013). Modeling the rate of senescence: can estimated biological age
 predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med
- 361 Sci, 68:667-674.
- Klemera P, Doubal S (2006). A new approach to the concept and computation of
 biological age. Mech Ageing Dev, 127:240-248.
- [16] Gao X, Geng T, Jiang M, Huang N, Zheng Y, Belsky DW, *et al.* (2023). Accelerated
 biological aging and risk of depression and anxiety: evidence from 424,299 UK
- Biobank participants. Nat Commun, 14:2277.
- 367 [17] Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, et al. (2023).
- FinnGen provides genetic insights from a well-phenotyped isolated population. Nature,
 613:508-518.
- Moturi S, Ghosh-Choudhary SK, Finkel T (2022). Cardiovascular disease and the
 biology of aging. J Mol Cell Cardiol, 167:109-117.
- 372 [19] North BJ, Sinclair DA (2012). The intersection between aging and cardiovascular
 373 disease. Circ Res, 110:1097-1108.
- Zhang X, Zhao H, Li Z, Liu X, Zhang Y, Yang N, *et al.* (2024). Accelerated biological
 aging, healthy behaviors, and genetic susceptibility with incidence of stroke and its

- 376 subtypes: A prospective cohort study. Aging Cell:e14427.
- 377 [21] Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. (1999).
- 378 Mammalian telomeres end in a large duplex loop. Cell, 97:503-514.
- 379 [22] Leao R, Apolonio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P (2018).
- 380 Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical
- 381 impacts in cancer. J Biomed Sci, 25:22.
- 382 [23] Atturu G, Brouilette S, Samani NJ, London NJ, Sayers RD, Bown MJ (2010). Short
- 383 leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). Eur J
- 384 Vasc Endovasc Surg, 39:559-564.
- 385 [24] Villard C, Hultgren R (2018). Abdominal aortic aneurysm: Sex differences. Maturitas,
 386 109:63-69.
- Makrygiannis G, Courtois A, Drion P, Defraigne JO, Kuivaniemi H, Sakalihasan N
 (2014). Sex differences in abdominal aortic aneurysm: the role of sex hormones. Ann
 Vasc Surg, 28:1946-1958.
- 390 [26] Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, et al. (2024). Associations between
- 391 biological ageing and the risk of, genetic susceptibility to, and life expectancy
- 392 associated with rheumatoid arthritis: a secondary analysis of two observational studies.
- 393 Lancet Healthy Longev, 5:e45-e55.
- Yang L, Wu X, Bian S, Zhao D, Fang S, Yuan H (2024). SIRT6-mediated vascular
 smooth muscle cells senescence participates in the pathogenesis of abdominal aortic
 aneurysm. Atherosclerosis, 392:117483.
- 397 [28] Raucci A, Macri F, Castiglione S, Badi I, Vinci MC, Zuccolo E (2021). MicroRNA-34a:

398		the bad guy in age-related vascular diseases. Cell Mol Life Sci, 78:7355-7378.
399	[29]	Ungvari Z, Bailey-Downs L, Sosnowska D, Gautam T, Koncz P, Losonczy G, et al.
400		(2011). Vascular oxidative stress in aging: a homeostatic failure due to dysregulation
401		of NRF2-mediated antioxidant response. Am J Physiol Heart Circ Physiol,
402		301:H363-372.
403	[30]	Xie J, Tang Z, Chen Q, Jia X, Li C, Jin M, et al. (2023). Clearance of Stress-Induced
404		Premature Senescent Cells Alleviates the Formation of Abdominal Aortic Aneurysms.
405		Aging Dis, 14:1778-1798.
406		

407 **Figure legends:**

- 408 Figure 1. Association between biological aging and the risk of AAA using restricted409 cubic splines model with three knots.
- 410 Abbreviation: AAA, abdominal aortic aneurysm; KDM-BA, Klemera-Doubal method
- 411 biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.
- 412 **Figure 2.** Separate and joint association of biological aging with the risk of AAA in
- 413 individuals with different levels of genetic susceptibility.
- 414 The result was presented as HR (95% CI) using the Cox proportional hazards model
- 415 adjusted for age, sex, ethnicity, Townsend deprivation index, education levels, body
- 416 mass index, C-reactive protein, smoking and drinking status, physical activity, sleep
- 417 and diet patterns, history of hyperlipemia, hypertension, and diabetes mellitus
- 418 Abbreviation: AAA, abdominal aortic aneurysm; KDM-BA, Klemera-Doubal method
- 419 biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.

X 7. • 11		Telomere length						
variables	Iotai	Q4	Q3	Q2	Q1	<i>p</i> value		
N	311646	77912	77911	77911	77912			
Age (years)	58.00 [50.00, 63.00]	55.00 [47.00, 61.00]	57.00 [49.00, 62.00]	58.00 [51.00, 63.00]	60.00 [53.00, 65.00]	< 0.001		
Women, n (%)	168249 (54.0)	46842 (60.1)	43183 (55.4)	40641 (52.2)	37583 (48.2)	< 0.001		
White, n (%)	294574 (94.5)	72266 (92.8)	73538 (94.4)	74127 (95.1)	74643 (95.8)	< 0.001		
TDI	-2.20 [-3.67, 0.39]	-2.13 [-3.63, 0.51]	-2.19 [-3.67, 0.39]	-2.22 [-3.68, 0.33]	-2.24 [-3.68, 0.34]	< 0.001		
Education, n (%)						< 0.001		
College	101091 (32.4)	28303 (36.3)	25913 (33.3)	24385 (31.3)	22490 (28.9)			
High school	35071 (11.3)	9517 (12.2)	8918 (11.4)	8696 (11.2)	7940 (10.2)			
Middle school	67420 (21.6)	16538 (21.2)	16993 (21.8)	16990 (21.8)	16899 (21.7)			
Others	108064 (34.7)	23554 (30.2)	26087 (33.5)	27840 (35.7)	30583 (39.3)			
BMI, Kg/m ²	26.68 [24.11, 29.79]	26.33 [23.81, 29.44]	26.64 [24.06, 29.76]	26.78 [24.20, 29.86]	26.98 [24.39, 30.07]	< 0.001		
CRP, mg/L	1.30 [0.64, 2.67]	1.19 [0.59, 2.50]	1.27 [0.63, 2.61]	1.32 [0.66, 2.70]	1.41 [0.71, 2.85]	< 0.001		
Drinking status, n (%)						< 0.001		
Never	13303 (4.3)	3577 (4.6)	3402 (4.4)	3179 (4.1)	3145 (4.0)			
Previous	10545 (3.4)	2586 (3.3)	2595 (3.3)	2578 (3.3)	2786 (3.6)			
Current	287103 (92.1)	71568 (91.9)	71750 (92.1)	71978 (92.4)	71807 (92.2)			

Table 1. Baseline characteristics of study participants grouped by telomere length quartiles.

Smoking status, n (%)						< 0.001
Never	171217 (54.9)	45181 (58.0)	43698 (56.1)	42177 (54.1)	40161 (51.5)	
Previous	107241 (34.4)	24874 (31.9)	26162 (33.6)	27418 (35.2)	28787 (36.9)	
Current	31733 (10.2)	7496 (9.6)	7714 (9.9)	7948 (10.2)	8575 (11.0)	
Physical activity, n						< 0.001
Regular	122958 (39.5)	31809 (40.8)	31060 (39.9)	30289 (38.9)	29800 (38.2)	
Excessive	75514 (24.2)	18426 (23.6)	18780 (24.1)	19133 (24.6)	19175 (24.6)	
Poor	43693 (14.0)	11063 (14.2)	10928 (14.0)	10956 (14.1)	10746 (13.8)	
Sleep pattern, n (%)						< 0.001
Healthy	151320 (48.6)	38635 (49.6)	38006 (48.8)	37521 (48.2)	37158 (47.7)	
Intermediate	100598 (32.3)	24512 (31.5)	25132 (32.3)	25319 (32.5)	25635 (32.9)	
Poor	5807 (1.9)	1337 (1.7)	1439 (1.8)	1475 (1.9)	1556 (2.0)	
Diet pattern, n (%)						< 0.001
Healthy	117408 (37.7)	30256 (38.8)	29456 (37.8)	29244 (37.5)	28452 (36.5)	
Intermediate	145882 (46.8)	35983 (46.2)	36512 (46.9)	36562 (46.9)	36825 (47.3)	
Poor	35506 (11.4)	8586 (11.0)	8806 (11.3)	8857 (11.4)	9257 (11.9)	
Medical history, n (%)						
Hyperlipidemia	144832 (46.5)	33301 (42.7)	35561 (45.6)	37139 (47.7)	38831 (49.8)	< 0.001
Hypertension	170827 (54.8)	38908 (49.9)	41630 (53.4)	43982 (56.5)	46307 (59.4)	< 0.001
Diabetes mellitus	17765 (5.7)	3562 (4.6)	4152 (5.3)	4597 (5.9)	5454 (7.0)	< 0.001

421 Abbreviation: TDI, Townsend deprivation index; CRP, C-reactive protein; BMI, body mass index.

422

X 7 • 11	Casas	T. • 1	Model	1	Model 2		
Variables	Cases/N	Incidence rate	HR (95%CI) p value		HR (95%CI)	p value	
Telomere length							
Q4	164/77912	1.703	1 (reference)		1 (reference)		
Q3	270/77911	2.813	1.26 (1.04, 1.53)	0.021	1.23 (1.02, 1.50)	0.034	
Q2	360/77911	3.765	1.38 (1.15, 1.66)	0.001	1.33 (1.11, 1.60)	0.002	
Q1	545/77912	5.755	1.67 (1.40, 1.99)	< 0.001	1.56 (1.31, 1.86)	< 0.001	
Continuous	1339/311646	3.499	1.23 (1.16, 1.29)	< 0.001	1.20 (1.14, 1.27)	< 0.001	
KDM-BA acceleration							
Q1	420/77912	4.386	1 (reference)		1 (reference)		
Q2	455/77911	4.764	1.61 (1.41, 1.84)	< 0.001	1.23 (1.08, 1.42)	0.003	
Q3	165/77911	1.715	1.93 (1.59, 2.34)	< 0.001	1.25 (1.02, 1.53)	0.034	
Q4	299/77912	3.143	3.18 (2.70, 3.75)	< 0.001	1.67 (1.37, 2.02)	< 0.001	
Continuous	1339/311646	3.499	1.53 (1.44, 1.62)	< 0.001	1.21 (1.12, 1.29)	< 0.001	
PhenoAge acceleration							
Q1	131/77912	1.349	1 (reference)		1 (reference)		
Q2	212/77911	2.197	1.28 (1.03, 1.59)	0.027	1.15 (0.93, 1.44)	0.202	
Q3	335/77911	3.497	1.81 (1.48, 2.22)	< 0.001	1.48 (1.20, 1.82)	< 0.001	
Q4	661/77912	7.09	3.36 (2.78, 4.06)	< 0.001	2.15 (1.76, 2.63)	< 0.001	
Continuous	1339/311646	3.499	1.61 (1.54, 1.70)	< 0.001	1.40 (1.32, 1.48)	< 0.001	

423	Table 2. A	ssociation	between	biol	ogical	aging	and t	the ri	isk of	abd	lominal	aortic	aneurv	/sm.
				0 I U I	0.0-0.00									

- ⁴²⁴ ^{*}The incidence rate was reported as per 10,000 person-years.
- 425 Model 1 adjusted for age, sex, ethnicity, Townsend deprivation index, education levels.
- 426 Model 2 adjusted for model 1 plus body mass index, C-reactive protein, smoking and drinking status, physical activity, sleep and diet patterns,
- 427 history of hyperlipemia, hypertension, and diabetes mellitus.
- 428 Abbreviation: KDM-BA, Klemera-Doubal method biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.

			e • / /•				
Subgroup	Cases/N	Q4	Q3	Q2	Q1	<i>p</i> for interaction	
Age						0.409	
<65	665/253654	1 (reference)	1.31 (1.01, 1.71)	1.63 (1.27, 2.10)	1.94 (1.52, 2.46)		
≥65	674/57992	1 (reference)	1.06 (0.83, 1.36)	1.26 (1.00, 1.60)	1.63 (1.30, 2.03)		
Sex						0.018	
Women	205/168249	1 (reference)	0.84 (0.55, 1.29)	0.79 (0.52, 1.19)	1.00 (0.68, 1.47)		
Men	1134/143397	1 (reference)	1.32 (1.07, 1.62)	1.45 (1.19, 1.76)	1.69 (1.40, 2.04)		
Ethnicity						0.829	
White	1308/294574	1 (reference)	1.26 (1.04, 1.53)	1.32 (1.10, 1.60)	1.56 (1.31, 1.86)		
Non-White	31/17072	1 (reference)	1.21 (0.29, 5.09)	1.35 (0.35, 5.16)	1.99 (0.56, 7.03)		
TDI						0.557	
Low	411/104004	1 (reference)	1.55 (1.08, 2.24)	1.64 (1.15, 2.33)	1.84 (1.31, 2.58)		
Moderate	445/103925	1 (reference)	1.05 (0.77, 1.44)	1.02 (0.75, 1.38)	1.29 (0.97, 1.71)		
High	483/103717	1 (reference)	1.19 (0.85, 1.66)	1.47 (1.07, 2.02)	1.65 (1.22, 2.24)		
Education						0.519	
College	223/101091	1 (reference)	1.62 (1.01, 2.61)	1.43 (0.89, 2.29)	1.83 (1.17, 2.86)		
High school	109/35071	1 (reference)	2.06 (0.99, 4.31)	1.99 (0.97, 4.09)	2.39 (1.19, 4.76)		
Middle school	289/67420	1 (reference)	1.12 (0.75, 1.69)	1.28 (0.87, 1.88)	1.26 (0.87, 1.83)		
Others	718/108064	1 (reference)	1.15 (0.89, 1.49)	1.22 (0.96, 1.57)	1.61 (1.27, 2.02)		

Table 3. Subgroup analysis for the association between telomere length with the risk of abdominal aortic aneurysm.

Hypertension						0.647
No	235/140819	1 (reference)	1.82 (1.08, 3.06)	1.82 (1.10, 3.01)	2.12 (1.30, 3.44)	
Yes	1104/170827	1 (reference)	1.18 (0.96, 1.44)	1.26 (1.04, 1.53)	1.50 (1.24, 1.80)	
Hyperlipidemia						0.266
No	344/166814	1 (reference)	1.47 (0.97, 2.23)	1.72 (1.16, 2.56)	1.81 (1.23, 2.65)	
Yes	995/144832	1 (reference)	1.09 (0.88, 1.34)	1.21 (0.99, 1.48)	1.45 (1.19, 1.75)	
Diabetes						0.516
No	1201/293881	1 (reference)	1.20 (0.97, 1.47)	1.34 (1.10, 1.63)	1.55 (1.29, 1.87)	
Yes	138/17765	1 (reference)	1.25 (0.73, 2.14)	1.15 (0.68, 1.96)	1.32 (0.79, 2.21)	

430 Adjusted for age, sex, ethnicity, TDI, education levels body mass index, C-reactive protein, smoking and drinking status, physical activity, sleep

431 and diet patterns, history of hyperlipemia, hypertension, and diabetes mellitus.

432 Abbreviation: TDI, Townsend deprivation index.